ID   T24M [Human bladder carcinoma]
AC   CVCL_VL60
DR   cancercelllines; CVCL_VL60
DR   Wikidata; Q98133066
RX   PubMed=19105184;
RX   PubMed=29732388;
CC   Population: Caucasian; Swedish.
CC   Characteristics: Established from T24 by cycles of subcutaneous injections into SCID mice.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012600; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Ter (c.378C>G); ClinVar=VCV000578988; Zygosity=Homozygous (from parent cell line).
CC   Omics: Proteome analysis by 2D-DE/MS.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0554 ! T24
SX   Female
AG   82Y
CA   Cancer cell line
DT   Created: 07-09-18; Last updated: 05-10-23; Version: 10
//
RX   PubMed=19105184; DOI=10.1002/pmic.200800121;
RA   Makridakis M., Gagos S., Petrolekas A., Roubelakis M.G., Bitsika V.,
RA   Stravodimos K., Pavlakis K., Anagnou N.P., Coleman J., Vlahou A.;
RT   "Chromosomal and proteome analysis of a new T24-based cell line model
RT   for aggressive bladder cancer.";
RL   Proteomics 9:287-298(2009).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//